BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 33591888)

  • 41. Apparent diffusion coefficient and sodium concentration measurements in human prostate tissue via hydrogen-1 and sodium-23 magnetic resonance imaging in a clinical setting at 3T.
    Hausmann D; Konstandin S; Wetterling F; Haneder S; Nagel AM; Dinter DJ; Schönberg SO; Zöllner FG; Schad LR
    Invest Radiol; 2012 Dec; 47(12):677-82. PubMed ID: 22996314
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Feasibility of predicting pathological evaluation by ultrasonic evaluation in initial stage of neoadjuvant chemotherapy for primary breast cancer].
    Qi M; Li JF; Xie YT; Lu AP; Liu YQ; Lin BY; Ouyang T
    Zhonghua Yi Xue Za Zhi; 2010 Mar; 90(8):511-4. PubMed ID: 20367959
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Contrast-enhanced MRI after neoadjuvant chemotherapy of breast cancer: lesion-to-background parenchymal signal enhancement ratio for discriminating pathological complete response from minimal residual tumour.
    Kim SY; Cho N; Shin SU; Lee HB; Han W; Park IA; Kwon BR; Kim SY; Lee SH; Chang JM; Moon WK
    Eur Radiol; 2018 Jul; 28(7):2986-2995. PubMed ID: 29380033
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Early assessment of breast cancer response to neoadjuvant chemotherapy by semi-quantitative analysis of high-temporal resolution DCE-MRI: preliminary results.
    Abramson RG; Li X; Hoyt TL; Su PF; Arlinghaus LR; Wilson KJ; Abramson VG; Chakravarthy AB; Yankeelov TE
    Magn Reson Imaging; 2013 Nov; 31(9):1457-64. PubMed ID: 23954320
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effective factors to raise diagnostic performance of breast MRI for diagnosing pathologic complete response in breast cancer patients after neoadjuvant chemotherapy.
    Choi BB; Kim SH
    Acta Radiol; 2015 Jul; 56(7):790-7. PubMed ID: 24951616
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Role of the Intravoxel Incoherent Motion Diffusion Weighted Imaging in the Pre-treatment Prediction and Early Response Monitoring to Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer.
    Che S; Zhao X; Ou Y; Li J; Wang M; Wu B; Zhou C
    Medicine (Baltimore); 2016 Jan; 95(4):e2420. PubMed ID: 26825883
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Accuracy of Contrast-Enhanced Ultrasound Compared With Magnetic Resonance Imaging in Assessing the Tumor Response After Neoadjuvant Chemotherapy for Breast Cancer.
    Lee SC; Grant E; Sheth P; Garcia AA; Desai B; Ji L; Groshen S; Hwang D; Yamashita M; Hovanessian-Larsen L
    J Ultrasound Med; 2017 May; 36(5):901-911. PubMed ID: 28150325
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A machine learning model that classifies breast cancer pathologic complete response on MRI post-neoadjuvant chemotherapy.
    Sutton EJ; Onishi N; Fehr DA; Dashevsky BZ; Sadinski M; Pinker K; Martinez DF; Brogi E; Braunstein L; Razavi P; El-Tamer M; Sacchini V; Deasy JO; Morris EA; Veeraraghavan H
    Breast Cancer Res; 2020 May; 22(1):57. PubMed ID: 32466777
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Features from Computerized Texture Analysis of Breast Cancers at Pretreatment MR Imaging Are Associated with Response to Neoadjuvant Chemotherapy.
    Chamming's F; Ueno Y; Ferré R; Kao E; Jannot AS; Chong J; Omeroglu A; Mesurolle B; Reinhold C; Gallix B
    Radiology; 2018 Feb; 286(2):412-420. PubMed ID: 28980886
    [TBL] [Abstract][Full Text] [Related]  

  • 50.
    Arponen O; McLean MA; Nanaa M; Manavaki R; Baxter GC; Gill AB; Riemer F; Kennerley AJ; Woitek R; Kaggie JD; Brackenbury WJ; Gilbert FJ
    Eur Radiol Exp; 2024 Jun; 8(1):75. PubMed ID: 38853182
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The assessment of breast cancer response to neoadjuvant chemotherapy: comparison of magnetic resonance imaging and 18F-fluorodeoxyglucose positron emission tomography.
    Park JS; Moon WK; Lyou CY; Cho N; Kang KW; Chung JK
    Acta Radiol; 2011 Feb; 52(1):21-8. PubMed ID: 21498321
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Criteria for identifying residual tumours after neoadjuvant chemotherapy of breast cancers: a magnetic resonance imaging study.
    Kim Y; Sim SH; Park B; Chae IH; Han JH; Jung SY; Lee S; Kwon Y; Park IH; Ko K; Lee CW; Lee KS; Kang HS; Lee ES
    Sci Rep; 2021 Jan; 11(1):634. PubMed ID: 33436702
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Elevated tissue sodium concentration in malignant breast lesions detected with non-invasive 23Na MRI.
    Ouwerkerk R; Jacobs MA; Macura KJ; Wolff AC; Stearns V; Mezban SD; Khouri NF; Bluemke DA; Bottomley PA
    Breast Cancer Res Treat; 2007 Dec; 106(2):151-60. PubMed ID: 17260093
    [TBL] [Abstract][Full Text] [Related]  

  • 54. MRI in the evaluation of breast cancer patient response to neoadjuvant chemotherapy: predictive factors for breast conservative surgery.
    Nadrljanski MM; Miloševic ZC; Plešinac-Karapandžic V; Maksimovic R
    Diagn Interv Radiol; 2013; 19(6):463-70. PubMed ID: 24047722
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Computer-aided evaluation of breast MRI for the residual tumor extent and response monitoring in breast cancer patients receiving neoadjuvant chemotherapy.
    Lyou CY; Cho N; Kim SM; Jang M; Park JS; Baek SY; Moon WK
    Korean J Radiol; 2011; 12(1):34-43. PubMed ID: 21228938
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Optical mammography using diffuse optical spectroscopy for monitoring tumor response to neoadjuvant chemotherapy in women with locally advanced breast cancer.
    Schaafsma BE; van de Giessen M; Charehbili A; Smit VT; Kroep JR; Lelieveldt BP; Liefers GJ; Chan A; Löwik CW; Dijkstra J; van de Velde CJ; Wasser MN; Vahrmeijer AL
    Clin Cancer Res; 2015 Feb; 21(3):577-84. PubMed ID: 25473002
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Assessment of CAD-generated tumor volumes measured using MRI in breast cancers before and after neoadjuvant chemotherapy.
    Takeda K; Kanao S; Okada T; Kataoka M; Ueno T; Toi M; Ishiguro H; Mikami Y; Togashi K
    Eur J Radiol; 2012 Oct; 81(10):2627-31. PubMed ID: 22221829
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Intratumor partitioning and texture analysis of dynamic contrast-enhanced (DCE)-MRI identifies relevant tumor subregions to predict pathological response of breast cancer to neoadjuvant chemotherapy.
    Wu J; Gong G; Cui Y; Li R
    J Magn Reson Imaging; 2016 Nov; 44(5):1107-1115. PubMed ID: 27080586
    [TBL] [Abstract][Full Text] [Related]  

  • 59. MRI Volume Changes of Axillary Lymph Nodes as Predictor of Pathologic Complete Responses to Neoadjuvant Chemotherapy in Breast Cancer.
    Cattell RF; Kang JJ; Ren T; Huang PB; Muttreja A; Dacosta S; Li H; Baer L; Clouston S; Palermo R; Fisher P; Bernstein C; Cohen JA; Duong TQ
    Clin Breast Cancer; 2020 Feb; 20(1):68-79.e1. PubMed ID: 31327729
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Monitoring the size and response of locally advanced breast cancers to neoadjuvant chemotherapy (weekly paclitaxel and epirubicin) with serial enhanced MRI.
    Cheung YC; Chen SC; Su MY; See LC; Hsueh S; Chang HK; Lin YC; Tsai CS
    Breast Cancer Res Treat; 2003 Mar; 78(1):51-8. PubMed ID: 12611457
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.